High Cell-Free DNA Levels in Cerebrospinal Fluid Predict Leptomeningeal Seeding of Hematologic Malignancy
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose The main difficulty when diagnosing leptomeningeal metastases (LMSs) is the low sensitivity of cytology. Cancer cells release cell-free DNA (cfDNA) during proliferation and apoptosis, and so we analyzed the cfDNA level as a biomarker for LMSs in hematologic malignancy. Methods This study prospectively enrolled 20 patients with hematologic malignancy who underwent cerebrospinal fluid (CSF) analysis. LMS was diagnosed based on both CSF cytology and clinical findings. Results The CSF level of cfDNA was higher in patients with LMSs (108.17±84.84 ng/mL, mean±standard deviation) than in non-LMS patients (14.23±2.78 ng/mL). The sensitivity of cfDNA was higher than that of cytology (100% vs. 87%). Conclusions The cfDNA level in the CSF can be used as a supplemental marker for diagnosing LMS in hematologic malignancy patients.
Abstract
Background and Purpose The main difficulty when diagnosing leptomeningeal metastases (LMSs) is the low sensitivity of cytology. Cancer cells release cell-free DNA (cfDNA) during proliferation and apoptosis, and so we analyzed the cfDNA level as a biomarker for LMSs in hematologic malignancy. Methods This study prospectively enrolled 20 patients with hematologic malignancy who underwent cerebrospinal fluid (CSF) analysis. LMS was diagnosed based on both CSF cytology and clinical findings. Results The CSF level of cfDNA was higher in patients with LMSs (108.17±84.84 ng/mL, mean±standard deviation) than in non-LMS patients (14.23±2.78 ng/mL). The sensitivity of cfDNA was higher than that of cytology (100% vs. 87%). Conclusions The cfDNA level in the CSF can be used as a supplemental marker for diagnosing LMS in hematologic malignancy patients.
참고문헌 (15)
- Lee EQ, "Nervous system metastases from systemic cancer", Continuum (Minneap Minn), 21, pp.415~428 (2015)
- Clarke JL, "Leptomeningeal metastasis from systemic cancer", Continuum (Minneap Minn), 18, pp.328~342 (2012)
- Seoane J, "Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases", Ann Oncol, 30, pp.211~218 (2019)
- Kaplan JG, "Leptomeningeal metastases : comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias", J Neurooncol, 9, pp.225~229 (1990)
- Mack F, "Therapy of leptomeningeal metastasis in solid tumors", Cancer Treat Rev, 43, pp.83~91 (2016)
- Groves MD, "Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma", J Neurooncol, 94, pp.229~234 (2009)
- Zhang Z, "Diagnostic value of CYFRA 21-1 in the cerebrospinal fluid for leptomeningeal metastasis", Dis Markers, 2017, pp.2467870~ (2017)
- Galicia N, "CSF analysis for protein biomarker identification in patients with leptomeningeal metastases from CNS lymphoma", Expert Rev Proteomics, 14, pp.363~372 (2017)
- Husain N, "Vascular endothelial growth factor as a marker of disease activity in neurotuberculosis", J Infect, 56, pp.114~119 (2008)
- Weinberg DG, "Moyamoya disease : a review of histopathology, biochemistry, and genetics", Neurosurg Focus, 30, pp.E20~ (2011)
- Husain H, "Cell-free DNA from ascites and pleural effusions : molecular insights into genomic aberrations and disease biology", Mol Cancer Ther, 16, pp.948~955 (2017)
- Lu T, "Clinical applications of urinary cell-free DNA in cancer : current insights and promising future", Am J Cancer Res, 7, pp.2318~2332 (2017)
- Leal T, "Leptomeningeal metastasis : challenges in diagnosis and treatment", Curr Cancer Ther Rev, 7, pp.319~327 (2011)
- Connolly ID, "A pilot study on the use of cerebrospinal fluid cell-free DNA in intramedullary spinal ependymoma", J Neurooncol, 135, pp.29~36 (2017)
- Tubergen DG, "Blasts in CSF with a normal cell count do not justify alteration of therapy for acute lymphoblastic leukemia in remission : a Childrens Cancer Group study", J Clin Oncol, 12, pp.273~278 (1994)